NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference
Most psychedelic experiences pass without incident, but when one turns into a crisis, the people who respond are usually EMS crews, emergency department staff, crisis counselors, and police. Very few have ever been tr...
Effects of Repeated Ketamine Infusions on Suicidal Ideation in Treatment-Resistant Depression and Associated Changes in Selected Plasma Biomarkers
In this secondary analysis of an open-label study of outpatients with treatment-resistant depression, four 0.5 mg/kg ketamine infusions over two weeks were associated with modest decreases in suicidal-ideation items o...
Effects of Repeated Ketamine Infusions on Suicidal Ideation in Treatment-Resistant Depression and Associated Changes in Selected Plasma Biomarkers
In this secondary analysis of an open-label study of outpatients with treatment-resistant depression, four 0.5 mg/kg ketamine infusions over two weeks were associated with modest decreases in suicidal-ideation items o...
Josh Hardman’s Q3 2026 quarterly briefing reviews major developments in psychedelic drug development, policy, regulation, science and academia, and previews the next quarter.
The Q3 2026 briefing, dated 2 October 2026, covers major developments from the prior quarter across psychedelic drug development, policy and regulation, science and academia. Founder and Editor Josh Hardman also looks...
Definium Therapeutics is developing DT120, a 100 µg oral LSD therapy for GAD and MDD, with modelled annual pricing of $28,000 to $70,000 and an eight-hour monitoring requirement.
Formerly MindMed, Definium is preparing DT120 for potential commercialisation after positive Phase 3 results in generalized anxiety disorder and major depressive disorder. The company has not set a final price and is ...
Single psilocybin dose linked to increased social exploration in OCD mouse model
Obsessive–compulsive disorder (OCD) is a psychiatric condition characterized by recurrent obsessions, or unwanted thoughts, typically accompanied by repeated actions that seem difficult to control, also known as compu...
A US survey found the highest reported rates of adverse effects among ibogaine and 5-MeO-DMT users, including cardiac symptoms and thoughts of death or suicide.
The cross-sectional study included 1,964 US adults from the 2025 National Survey Investigating Hallucinogenic Trends. Past three-month adverse effects were reported by 94.8% of ibogaine users and 92.8% of 5-MeO-DMT us...
After the Trip: A Qualitative Study of Healthy Individuals' Motor Experiences Following Different Doses of Psilocybin
This qualitative study interviewed 12 healthy adults after movement tasks under psilocybin doses of 5–20 mg. Participants described mixed changes in movement, coordination and reaction time that interacted with attent...
After the Trip: A Qualitative Study of Healthy Individuals' Motor Experiences Following Different Doses of Psilocybin
This qualitative study interviewed 12 healthy adults after movement tasks under psilocybin doses of 5–20 mg. Participants described mixed changes in movement, coordination and reaction time that interacted with attent...
September 2026 Newsletter
The dust is settling and we’re so curious to learn from our Burning…
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing…
Weekly Psychedelic Policy Briefing: September 30th, 2026
DEA proposed placing five tryptamines in Schedule I, including the active compound in a postpartum depression drug FDA designated a breakthrough therapy in February. Oregon dropped its psilocybin fee hikes, and a GAO ...
Can You Actually Stop a Bad Trip?
Here's everything you need to know about "trip killers," according to a neurologist. [...] Read More...
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce…
Compass Pathways Appoints Kelley Boucher as Chief People Officer
LONDON & NEW YORK, September 30, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the…